Related Experiment Video
Updated: Jun 4, 2025
12:22
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.5K
Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma
Silvia Angori1, Harini Lakshminarayanan1, Amir Banaei-Esfahani1
1Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
International Journal of Cancer
|December 21, 2024
Summary
Papillary renal cell carcinoma (pRCC) lacks targeted treatments. This study reveals NRF2-ARE pathway involvement in pRCC, identifying NQO1 as a poor survival marker and potential drug targets like Brusatol for MET-independent pRCC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Papillary renal cell carcinoma (pRCC) is the second most common kidney cancer subtype.
- Currently, pRCC lacks specific targeted therapies, especially for non-MET-driven cases.
- The NRF2-ARE pathway is implicated in pRCC development and progression.
Purpose of the Study:
- To investigate the role of the NRF2-ARE pathway in pRCC.
- To identify potential therapeutic targets for pRCC, particularly MET-independent subtypes.
Main Methods:
- Copy number analysis and Whole Exome Sequencing of 60 pRCC samples.
- Immunohistochemistry (IHC) for NQO1 expression on tissue microarrays (TMAs).
- Enzymatic activity assays and drug profiling of patient-derived pRCC cells (PDCs) with NRF2-ARE pathway inhibitors.
Main Results:
- Mutations in MET (5%) and NRF2-ARE pathway genes (10%) were identified in pRCC samples.
- Increased NQO1 expression correlated with poor survival, high tumor grade, and advanced stage in pRCC.
- NQO1 levels and activity were elevated in 56% of pRCC tissues and PDCs, with Brusatol and Convallatoxin showing promise as novel therapeutic agents.
Conclusions:
- The NRF2-ARE pathway is significantly involved in pRCC pathogenesis.
- NQO1 serves as a prognostic biomarker for poor survival in pRCC.
- Inhibiting the NRF2 pathway presents a novel therapeutic strategy for MET-independent pRCC.
Keywords:
NQO1NRF2‐ARE pathwaydrug sensitivity profilespapillary renal cell carcinomapatient‐derived cellstranslational medicineMore Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
01:07MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:26NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K